SHINE Medical Technologies, Inc. (SHINE), a Wisconsin-based company dedicated to being the world leader in safe, clean, and affordable production of medical isotopes and cancer treatment elements, has submitted its Construction Permit application to the Nuclear Regulatory Commission (NRC). This submittal is the first formal step by SHINE in seeking an NRC permit to begin construction of its medical isotope facility in Janesville, Wisconsin.
As required by Federal regulations, the Construction Permit application consists of general information about SHINE, an analysis of environmental impacts from the construction and operation of the facility, if any, and a preliminary safety analysis of the planned facility. Today’s filing includes the environmental analysis and general and financial information about SHINE; the remaining portions of the preliminary analysis will be filed in the next several months.
SHINE’s filing begins the NRC’s process of formal acceptance and review, which is expected to
take approximately eighteen months. “This filing is an important milestone as SHINE carries out its plans to construct and operate a facility to produce medical isotopes in Janesville,” said SHINE CEO and founder Greg Piefer. “It represents a lot of hard work by our tem and is a significant step forward for building and operating a facility that will address an important worldwide health care issue.